Status: Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
Participants needed: 178
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shenzhen Ionova Life Sciences Co., Ltd.Updated: Jun 10, 2026Locations: 1
Eligibility criteria
Written informed consent obtained. [+9]
Have protocol-defined toxicities within 28 days before the start of study treatm... [+17]